ATE81287T1 - Am zielorgan wirkendes enterales abgabesystem. - Google Patents

Am zielorgan wirkendes enterales abgabesystem.

Info

Publication number
ATE81287T1
ATE81287T1 AT86309305T AT86309305T ATE81287T1 AT E81287 T1 ATE81287 T1 AT E81287T1 AT 86309305 T AT86309305 T AT 86309305T AT 86309305 T AT86309305 T AT 86309305T AT E81287 T1 ATE81287 T1 AT E81287T1
Authority
AT
Austria
Prior art keywords
capsule
active ingredient
absorption
targeted
delivery system
Prior art date
Application number
AT86309305T
Other languages
English (en)
Inventor
John Desmond Davies
Elka Touitou
Arnold Rubinstein
Original Assignee
Scherer Corp R P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scherer Corp R P filed Critical Scherer Corp R P
Application granted granted Critical
Publication of ATE81287T1 publication Critical patent/ATE81287T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
AT86309305T 1985-11-29 1986-11-28 Am zielorgan wirkendes enterales abgabesystem. ATE81287T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL77186A IL77186A0 (en) 1985-11-29 1985-11-29 Pharmaceutical insulin composition
EP86309305A EP0225189B1 (de) 1985-11-29 1986-11-28 Am Zielorgan wirkendes enterales Abgabesystem

Publications (1)

Publication Number Publication Date
ATE81287T1 true ATE81287T1 (de) 1992-10-15

Family

ID=11056458

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86309305T ATE81287T1 (de) 1985-11-29 1986-11-28 Am zielorgan wirkendes enterales abgabesystem.

Country Status (7)

Country Link
US (1) US4910021A (de)
EP (1) EP0225189B1 (de)
JP (1) JP2633843B2 (de)
AT (1) ATE81287T1 (de)
DE (1) DE3686936T2 (de)
ES (1) ES2035821T3 (de)
IL (1) IL77186A0 (de)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645504B1 (en) * 1987-06-24 2003-11-11 Autoimmune Inc. Bystander suppression of type I diabetes by oral administration of glucagon
US5472710A (en) * 1988-04-16 1995-12-05 Schwarz Pharma Ag Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture
EP0351651B1 (de) * 1988-07-21 1993-09-15 F. Hoffmann-La Roche Ag Insulinzubereitung
US5350741A (en) * 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
JP2792862B2 (ja) * 1988-07-30 1998-09-03 寛治 高田 経口腸溶製剤
ES2077023T3 (es) * 1989-03-10 1995-11-16 Yamanouchi Pharma Co Ltd Material de recubrimiento que controla la liberacion de un medicamento para formulaciones de actividad prolongada.
DE3919982A1 (de) * 1989-06-19 1990-12-20 Liedtke Pharmed Gmbh Orale lipidarzneiform
DE69006662T2 (de) * 1989-08-21 1994-05-26 Hoffmann La Roche Insulinzubereitung für nicht-parenterale Verabreichung.
EP0422290A1 (de) * 1989-10-09 1991-04-17 Eli Lilly And Company Arzneimittel-Abgabesystem
IT1237197B (it) * 1989-11-16 1993-05-26 Sclavo Spa Formulazioni farmaceutiche anidre e forme di dosaggio per la somministrazione rettale di calcitonina.
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
EP0544671A4 (en) * 1990-04-18 1993-09-15 The University Of Utah Colonic-targeted oral drug-dosage forms based on crosslinked hydrogels containing azobonds and exhibiting ph-dependent swelling
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
EP0459516A1 (de) * 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Orale Arzneimittelformen von biologisch aktiven Eiweisstoffen
JPH064531B2 (ja) * 1990-06-04 1994-01-19 アイセロ化学株式会社 大腸崩壊性硬質カプセル
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
FR2673376A1 (fr) * 1991-03-01 1992-09-04 Lefesvre Andre Composition pharmaceutique pour le traitement des tumeurs de kaposi.
EP0517412A1 (de) * 1991-06-03 1992-12-09 MERCK SHARP & DOHME LTD. Pharmazeutische Zusammensetzungen enthaltend eine Benzodiazepen
US6764697B1 (en) * 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
JP2650578B2 (ja) * 1992-08-27 1997-09-03 日本エランコ株式会社 硬質カプセル用ゼラチン皮膜組成物及び易溶性硬質ゼラチンカプセル
US5358502A (en) * 1993-02-25 1994-10-25 Pfizer Inc PH-triggered osmotic bursting delivery devices
US5651983A (en) * 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
US5686105A (en) * 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5656290A (en) * 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
WO1994021591A1 (fr) * 1993-03-25 1994-09-29 Kao Corporation Preparation dermatologique et nouveau derive d'acide benzoique
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
US5424289A (en) * 1993-07-30 1995-06-13 Alza Corporation Solid formulations of therapeutic proteins for gastrointestinal delivery
AU7273494A (en) * 1993-09-01 1995-03-22 Pfizer Inc. Pharmaceutical compositions containing anionic surfactants
DE4329503A1 (de) * 1993-09-01 1995-03-02 Galenik Labor Freiburg Gmbh Pharmazeutische Präparate zur gezielten Behandlung von Morbus Crohn und Colitis Ulcerosa
US6204243B1 (en) 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
GB9325445D0 (en) 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
WO1995022981A1 (en) * 1994-02-24 1995-08-31 Nippon Chemiphar Co., Ltd. Oral synthetic peptide preparation
SE9400918L (sv) * 1994-03-18 1995-09-19 Anne Fjellstad Paulsen Stabiliserad komposition för oral administrering av peptider
GB2303550B (en) * 1994-06-21 1998-07-08 Danbiosyst Uk Colonic drug delivery system
GB9412394D0 (en) * 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
US5536507A (en) * 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
CN1088580C (zh) 1994-12-22 2002-08-07 阿斯特拉公司 气溶胶药物制剂
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5686106A (en) * 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
US5817624A (en) * 1995-06-05 1998-10-06 Alza Corporation Permeation enhancer compositions for increased absorption of therapeutic proteins through the colonic membrane
SG80553A1 (en) * 1995-07-20 2001-05-22 Tanabe Seiyaku Co Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
JPH10152431A (ja) * 1996-08-02 1998-06-09 Hisamitsu Pharmaceut Co Inc 経口製剤用カプセルと経口カプセル製剤
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
KR20010012402A (ko) * 1997-05-09 2001-02-15 세이지 파마슈티칼스, 인크. 안정한 약제학적 경구 투여형
US6030641A (en) * 1997-06-03 2000-02-29 Uni Colloid Kabushiki Kaisha Sustained release capsule and method for preparing the same
US7094426B2 (en) * 1998-08-27 2006-08-22 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
ATE386804T1 (de) 1998-10-15 2008-03-15 Novartis Vaccines & Diagnostic Gene mit veränderter expression in metastatischen brust- oder dickdarm- krebszellen
JP2003524389A (ja) 1998-12-16 2003-08-19 カイロン コーポレイション ヒトサイクリン依存的キナーゼ（ｈＰＮＱＡＬＲＥ）
JP2000247911A (ja) 1999-02-26 2000-09-12 Hisamitsu Pharmaceut Co Inc 大腸用吸収促進剤
WO2000054775A1 (de) * 1999-03-12 2000-09-21 Basf Ag Stabile pharmazeutische anwendungsform für paroxetin-anhydrat
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US6620834B1 (en) 1999-07-02 2003-09-16 Hisamitsu Pharmaceutical Co., Inc. Medicinal compositions for treating colorectal cancer
ES2386317T3 (es) 2000-01-10 2012-08-17 Novartis Vaccines And Diagnostics, Inc. Genes expresados diferencialmente en cáncer de mama
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
WO2002072033A2 (en) * 2001-03-13 2002-09-19 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms containing glucocorticosteroid
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
EP1530505A4 (de) * 2001-11-30 2007-09-12 Bristol Myers Squibb Co Pipettenkonfigurationen und arrays dafür zur messung zellularer elektrischer eigenschaften
US6982253B2 (en) * 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
US7135324B2 (en) 2002-09-04 2006-11-14 The University Of Connecticut Viral recombinases, related articles, and methods of use thereof
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US20040062778A1 (en) * 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
US20040091544A1 (en) * 2002-11-08 2004-05-13 Ruff Michael D. Coated dibasic calcium phosphate
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
EP1643978A1 (de) * 2003-07-04 2006-04-12 Nycomed Danmark A/S Nebenschilddrüsenhormon (pth) mit pharmazeutischen zusammensetzungen zur oralen anwendung
CA2536906A1 (en) * 2003-08-27 2005-03-10 Vecta Ltd. Compositions for treating pathologies that necessitate suppression of gastric acid secretion
US20050118267A1 (en) * 2003-09-19 2005-06-02 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
AP2006003585A0 (en) * 2003-09-19 2006-04-30 Penwest Pharmaceuticals Co Delayed release dosage forms.
US20050152969A1 (en) * 2004-01-08 2005-07-14 Chiprich Timothy B. Colored liquid-filled soft capsules and method of manufacture thereof
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
US20040224019A1 (en) * 2004-03-03 2004-11-11 Adi Shefer Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
PE20060003A1 (es) * 2004-03-12 2006-03-01 Smithkline Beecham Plc Formulacion farmaceutica polimerica para moldear por inyeccion
JP4792390B2 (ja) 2004-03-29 2011-10-12 株式会社ガルファーマ 新規ガレクチン９改変体タンパク質及びその用途
EP1750755A1 (de) * 2004-06-02 2007-02-14 Technion Research And Development Foundation, Ltd. Verfahren und formulierungen zur erhöhung der darmfunktion
CN1296098C (zh) * 2004-09-29 2007-01-24 薛南荣 口服胰岛素保护剂
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
US7964215B1 (en) * 2006-01-24 2011-06-21 Emet Pharmaceuticals, LLC Delayed release dosage form
ES2363452T3 (es) * 2006-07-06 2011-08-04 Ares Trading S.A. Una composición farmacéutica oral de una anilinopirimidina, su preparación y uso de la misma.
US8039010B2 (en) * 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2321341B1 (de) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
EP2344593A2 (de) * 2008-10-02 2011-07-20 Fujifilm Manufacturing Europe BV Antimikrobieller überzug
EP2762150A1 (de) * 2009-03-12 2014-08-06 Nordic Bioscience A/S Behandlung von Diabetes und Stoffwechselsyndrom
JP5660037B2 (ja) 2009-05-18 2015-01-28 Jsr株式会社 感放射線性樹脂組成物
US8663671B2 (en) * 2009-11-05 2014-03-04 Philip Morris Usa Inc. Methods and compositions for producing hydrogel capsules coated for low permeability and physical integrity
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2013003697A1 (en) 2011-06-30 2013-01-03 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
JP2013063970A (ja) * 2011-09-02 2013-04-11 Fujifilm Corp ソフトカプセル製剤、ソフトカプセル製剤用組成物、及びソフトカプセル製剤の製造方法
JP6499591B2 (ja) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9763887B2 (en) 2013-03-15 2017-09-19 Allergan Pharmaceuticals International Limited Mesalamine pharmaceutical composition with multiple dosage elements for reduced delivery variability
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
CA2926691A1 (en) 2013-10-10 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
CA2997915A1 (en) 2015-09-15 2017-03-23 C.B. Fleet Company, Incorporated Bisacodyl compositions and delivery apparatus
JP2019506383A (ja) 2016-01-11 2019-03-07 シナジー ファーマシューティカルズ インコーポレイテッド 潰瘍性大腸炎を治療するための製剤および方法
CN109776764B (zh) * 2019-01-23 2020-06-02 北京化工大学 一种超交联有机聚合物材料、制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617671C3 (de) * 1967-03-07 1980-07-03 A. Nattermann & Cie Gmbh, 5000 Koeln Weichgelatine-Kapseln mit erhöhter Wärmestabilität
YU36434B (en) * 1969-05-14 1984-02-29 Sanol Arznei Schwarz Gmbh Process for obtaining gelation capsules filled with the active substance resistant to gastric juice and dissolvable in the small intestine
US4022889A (en) * 1974-05-20 1977-05-10 The Upjohn Company Therapeutic compositions of antibiotic U-44,590 and methods for using the same
US4031215A (en) * 1974-11-11 1977-06-21 Kaken Chemical Co., Ltd. Streptovaricinone C derivatives as antibiotics
US4042688A (en) * 1975-11-24 1977-08-16 Control Drug, Inc. Method of providing high-protein nutrition by the oral administration of a predigested protein composition
US4406896A (en) * 1979-12-20 1983-09-27 Merck & Co., Inc. Adjuvants for rectal delivery of drug substances
US4464363A (en) * 1979-12-20 1984-08-07 Merck & Co., Inc. Ajuvants for rectal delivery of drug substances
NZ196349A (en) * 1980-03-07 1984-08-24 Interx Research Corp Enhancement of absorption rate of orally administered polar bioactive agents
JPS56128714A (en) * 1980-03-07 1981-10-08 Intaretsukusu Research Corp Oral absorption-improved beta-lactam antibiotic oral dosage
DE3171774D1 (en) * 1980-03-31 1985-09-19 Teijin Ltd Pharmaceutical composition for intrarectal administration, and suppository prepared therefrom
SE8003805L (sv) * 1980-05-21 1981-11-22 Haessle Ab En farmaceutisk beredning med forbettrade utlosningsegenskap
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
DE3046028A1 (de) * 1980-12-06 1982-07-15 LuK Lamellen und Kupplungsbau GmbH, 7580 Bühl Membranpumpe
JPS57146704A (en) * 1981-03-09 1982-09-10 Hokko Chem Ind Co Ltd Improved dust preparation for agricultural purpose
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
JPS6054313A (ja) * 1983-09-01 1985-03-28 Terumo Corp 腸管吸収性ヘパリン組成物
JPS6097917A (ja) * 1983-11-01 1985-05-31 Terumo Corp 腸管吸収性ウロキナ−ゼ組成物
JPS60215633A (ja) * 1984-04-11 1985-10-29 Terumo Corp 腸管吸収性ウロキナ−ゼリポソ−ム組成物

Also Published As

Publication number Publication date
ES2035821T3 (es) 1993-05-01
IL77186A0 (en) 1986-04-29
DE3686936T2 (de) 1993-04-29
EP0225189A2 (de) 1987-06-10
JP2633843B2 (ja) 1997-07-23
EP0225189A3 (en) 1987-12-16
US4910021A (en) 1990-03-20
EP0225189B1 (de) 1992-10-07
JPS62195324A (ja) 1987-08-28
DE3686936D1 (de) 1992-11-12

Similar Documents

Publication Publication Date Title
ATE81287T1 (de) Am zielorgan wirkendes enterales abgabesystem.
ATE210424T1 (de) Verzoegerte freisetzung von peptiden aus pharmazeutischen zusammensetzungen
DE69428040D1 (de) Orale darreichungsform
MY125662A (en) Pharmaceutical formulations containing darifenacin
PT825858E (pt) Capsulas de libertacao dependente do tempo contendo acidos poliinsaturados omega-3 para o tratamento da doenca inflamatoria do intestino
WO2000022909A3 (en) Systems for oral delivery
KR880003617A (ko) 경구용 고형제형과 그의 제조방법
DE68928920D1 (de) Fettsäure-arzneimittel-konjugat zur verabreichung von arzneimitteln durch die blut-gehirn-schranke
AU6764390A (en) Pharmaceutical granules and drug dosage units made therefrom
EP0177342A2 (de) Orale Formulierungen therapeutischer Proteine
ATE124255T1 (de) Im dickdarm zerfallende, polypeptide enthaltende orale formulierungen.
BE1000722A4 (fr) Compositions pharmaceutiques de polypeptides adaptees a la resorption gastro-intestinale.
FR2581873B1 (fr) Preparations pharmaceutiques a activite anti-hypertensive et cardioprotectrice contenant du verapamil, du triamterene et de l'hydrochlorothiazide
KR890004705A (ko) 항바이러스성 제제
JPS5551019A (en) Drug containing alllee or 133zz7*88dehydroo retine acid and manufacture thereof
GB1351437A (en) N-substituted amino acids having antiviral anti-inflammatory or anti-tumour activity
NZ219717A (en) Pharmaceutical formulations containing indomethacin, a metabolic carboxylic acid salt and a metabolisable carbohydrate
KR950700063A (ko) 외상후 스트레스 치료제로서의 브로파로민(Brofaromine as an agent for treating post-traumatic stress)
KR930000119A (ko) 신규 경구용 약제
KR890003399A (ko) 약리적 활성 화합물 및 용도
TH41464A (th) สารผสมทางเภสัชกรรม
MY114610A (en) Controlled drug delivery system for diltiazem.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee